InMed Pharmaceuticals to Merge with Mentari Therapeutics in All-Stock Deal, Securing $290M Private Placement
INM has more than doubled off its 52-week low of $0.575 on elevated volume (57× avg).
Summary
InMed Pharmaceuticals is merging with privately-held Mentari Therapeutics in an all-stock transaction, which includes a $290 million private placement, providing a new pipeline and significant funding for the combined entity.
Key Events · M&A and Partnerships · INM
-
Definitive Merger Agreement
InMed Pharmaceuticals Inc. has entered into a definitive merger agreement to acquire Mentari Therapeutics, Inc. in an all-stock transaction. The combined company will operate as Mentari Therapeutics, Inc. and trade on Nasdaq under a new ticker symbol.
-
Significant Private Placement
A concurrent, oversubscribed private placement of US$290 million into Mentari is expected to close immediately prior to the merger. This financing is projected to fund the combined company's operations through 2028.
-
Shareholder Ownership and Valuation
Pre-merger InMed shareholders are expected to own approximately 1.51% of the combined company, which is anticipated to have a pro forma equity value of approximately US$421.4 million. Mentari holders will own ~29.66%, and new investors from the private placement will own ~68.82%.
-
Contingent Value Rights for Legacy Assets
InMed shareholders of record prior to closing will receive Contingent Value Rights (CVRs), entitling them to 90% of net proceeds, if any, from the disposition of InMed's pre-merger legacy assets.
Analysis · INM · Life Sciences
This definitive merger agreement with Mentari Therapeutics is a transformative event for InMed Pharmaceuticals, which was previously facing substantial going concern doubts and Nasdaq delisting risks. The transaction includes a significant $290 million private placement, providing the combined company with a cash runway through 2028. While existing InMed shareholders will be heavily diluted, owning approximately 1.51% of the combined entity, they gain a stake in a much larger, well-funded biotechnology company with a new migraine prevention pipeline. This deal effectively provides a lifeline and a new strategic direction, addressing critical financial and operational challenges.
At the time of this filing, INM was trading at $1.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.58 to $7.98. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.